Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose cell transplantation is a cell therapy being investigated by the Chinese Academy of Sciences for the treatment of glottic insufficiency, particularly resulting from unilateral vocal cord paralysis (UVCP). The procedure involves harvesting adipose-derived cells, which include mesenchymal stem cells and other regenerative components, from the patient's own fat tissue and injecting them into the submucosa of the vocal cord and paraglottic space. This approach aims to provide bulk to the paralyzed vocal fold and promote laryngeal soft tissue regeneration, thereby improving voice quality and reducing symptoms like vocal fatigue and aspiration. In clinical studies, it is often evaluated alongside or in combination with functional collagen scaffolds to enhance tissue integration and structural support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose cell transplantation.